News

X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia

Webcast to take place on September 27 at 8:00 a.m. ET, followed by live Q&ABOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE)…

2 years ago

Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism

•   TransCon PTH could, if approved, become the first hormone replacement therapy to address the underlying cause of hypoparathyroidism, an…

2 years ago

Akoya to Participate at Four Upcoming Investor Conferences

MARLBOROUGH, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced…

2 years ago

Araris Biotech AG to Present at 13th Annual World ADC San Diego 2022

AU ZH, Switzerland, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker…

2 years ago

Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference

CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an…

2 years ago

BBS-Bioactive Bone Substitutes Plc: Change in BBS-Bioactive Bonesubstitutes Plc’s management

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 31 August 2022 15.00 (CEST) BBS-Bioactive Bonesubstitutes Plc's CFO and member of the management…

2 years ago

New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients

Myriad Genetics’ EndoPredict test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapySALT LAKE…

2 years ago

Optimi Health Enters Into International Collaborative Research and Supply Agreement With Promises Innovative Recovery Center

Company encouraged by medicinal and therapeutic regulatory developments in Costa Rica Z Strain Psilocybe cubensis Optimi Health, Z Strain Psilocybe…

2 years ago

Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

NEW YORK and PETAH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:…

2 years ago